Last reviewed · How we verify

iRBD

Beijing Friendship Hospital · FDA-approved active Small molecule

iRBD is an integrated rapid behavioral diagnostic system designed to assess and monitor rapid eye movement sleep behavior disorder through automated analysis.

iRBD is an integrated rapid behavioral diagnostic system designed to assess and monitor rapid eye movement sleep behavior disorder through automated analysis. Used for Rapid eye movement sleep behavior disorder (RBD) diagnosis and monitoring.

At a glance

Generic nameiRBD
SponsorBeijing Friendship Hospital
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

iRBD appears to be a diagnostic or monitoring tool rather than a pharmacological agent, likely combining imaging, behavioral assessment, and data analytics to evaluate RBD symptoms and progression. The exact mechanistic details of how it functions are not well-established in publicly available literature.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: